Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 7,024 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Volunteers. Clear all

Conditions: Healthy Subjects
Interventions: Glepaglutide; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Elderly Volunteers
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years to 80 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Opioid-Related Disorders, Substance-Related Disorders
Interventions: 10% N2O, 20% N2O, 30% N2O, 40% N2O; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 37 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 1996
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: ILV-094; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: NRX-1074, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
Interventions: V4020; Biological
Lead sponsor: Medigen, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alzheimer Disease
Interventions: [18F] PBR111; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hyperalgesia, Allodynia
Interventions: Fenobam, Placebo; Drug
Lead sponsor: Laura Cavallone; Other
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Volunteers
Interventions: (2R,6R)-Hydroxynorketamine, Placebo; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: South Miami, Florida • Austin, Texas

Conditions: Anthrax, Anthrax Immunisation
Interventions: AV7909; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 40 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of Digoxin, Healthy Volunteers
Interventions: Isavuconazole, digoxin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: Emraclidine, Itraconazole, Carbamazepine, Metformin; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Surgery
Interventions: Chlorhexidine Gluconate, Vehicle, DynaHex-2; Drug · Other
Lead sponsor: Medline Industries; Industry
Eligibility: 16 Years and older
Enrollment: 879 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Butte, Montana

Conditions: Healthy Volunteers, Sickle Cell Disease
Interventions: FT-4202/Placebo; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Long Beach, California • Oakland, California + 12 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 4 Years to 12 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2010
U.S. locations: 4
States / cities: Little Rock, Arkansas • Gainesville, Florida • New York, New York + 1 more

Conditions: Psychedelic Experiences, Amnesia
Interventions: Psilocybin and Midazolam; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: SHP643; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions: LFF269, Placebo to LFF269; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV
Interventions: Ritonavir, Cobicistat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anthocyanins
Interventions: ACRB, Placebo; Dietary Supplement · Other
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Healthy
Interventions: Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Neurologic Disorders, Autism, Neurodegenerative Disease, Neurobehavioral Manifestation
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 6 Weeks and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

Effects of Nitrous Oxide: A Dose-Response Analysis - 5

Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects

Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers

A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers

Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers

Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers

A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes

Anthrax AV7909 Liquid vs Lyophilized

Relationship of Dopamine to Cognitive Function in Parkinson's Disease

Drug Interaction Study of Isavuconazole and Digoxin

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Preoperative CHG Cloth on Healthy Subjects

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

Characterization of Childhood-Onset Obsessive-Compulsive Disorder

Pilot RECAP Study in Healthy Volunteers

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

Inflammatory and Metabolic Responses to Long-term Dietary Supplementation With Anthocyanin-rich Blend

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions

The Neurodevelopmental and Behavioral Phenotyping Screening Protocol